22nd Century Retained Earnings (Accumulated Deficit) 2011-2024 | XXII
22nd Century retained earnings (accumulated deficit) from 2011 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
22nd Century Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-379 |
| 2022 |
$-238 |
| 2021 |
$-178 |
| 2020 |
$-145 |
| 2019 |
$-126 |
| 2018 |
$-99 |
| 2017 |
$-91 |
| 2016 |
$-78 |
| 2015 |
$-67 |
| 2014 |
$-56 |
| 2013 |
$-40 |
| 2012 |
$-14 |
| 2011 |
$-7 |
| 2010 |
$-6 |
22nd Century Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$-386 |
| 2024-03-31 |
$-384 |
| 2023-12-31 |
$-379 |
| 2023-09-30 |
$-349 |
| 2023-06-30 |
$-277 |
| 2023-03-31 |
$-256 |
| 2022-12-31 |
$-238 |
| 2022-09-30 |
$-212 |
| 2022-06-30 |
$-198 |
| 2022-03-31 |
$-187 |
| 2021-12-31 |
$-178 |
| 2021-09-30 |
$-164 |
| 2021-06-30 |
$-155 |
| 2021-03-31 |
$-150 |
| 2020-12-31 |
$-145 |
| 2020-09-30 |
$-139 |
| 2020-06-30 |
$-135 |
| 2020-03-31 |
$-130 |
| 2019-12-31 |
$-126 |
| 2019-09-30 |
$-119 |
| 2019-06-30 |
$-109 |
| 2019-03-31 |
$-101 |
| 2018-12-31 |
$-99 |
| 2018-09-30 |
$-90 |
| 2018-06-30 |
$-97 |
| 2018-03-31 |
$-90 |
| 2017-12-31 |
$-91 |
| 2017-09-30 |
$-87 |
| 2017-06-30 |
$-84 |
| 2017-03-31 |
$-81 |
| 2016-12-31 |
$-78 |
| 2016-09-30 |
$-75 |
| 2016-06-30 |
$-73 |
| 2016-03-31 |
$-70 |
| 2015-12-31 |
$-67 |
| 2015-09-30 |
$-64 |
| 2015-06-30 |
$-61 |
| 2015-03-31 |
$-60 |
| 2014-12-31 |
$-56 |
| 2014-09-30 |
$-50 |
| 2014-06-30 |
$-47 |
| 2014-03-31 |
$-45 |
| 2013-12-31 |
$-40 |
| 2013-09-30 |
$-32 |
| 2013-06-30 |
$-17 |
| 2013-03-31 |
$-16 |
| 2012-12-31 |
$-14 |
| 2012-09-30 |
$-9 |
| 2012-06-30 |
$-9 |
| 2012-03-31 |
$-9 |
| 2011-12-31 |
$-7 |
| 2011-09-30 |
$-8 |
| 2011-06-30 |
$-7 |
| 2011-03-31 |
$-6 |
| 2010-12-31 |
$-6 |
| Sector |
Industry |
Market Cap |
Revenue |
| Consumer Staples |
Tobacco Products |
$0.002B |
$0.032B |
|
22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York.
|
